The present invention provides processes for producing visibly clear aqueous consumable products. Consumable products may include compositions for solubilizing water-insoluble and poorly water-soluble or poorly permeable active ingredients such as drugs, nutritional supplements, and essential oils. The compositions are useful for administration of the active ingredient to the subject via various routes and provide good bioavailability of the active. The compositions are generally clear and non-turbid and are useful, for example, for preparing formulations of cannabinoid compounds.

The present invention provides processes for producing visibly clear aqueous consumable products. Consumable products may include compositions for solubilizing water-insoluble and poorly water-soluble or poorly permeable active ingredients such as drugs, nutritional supplements, and essential oils. The compositions are useful for administration of the active ingredient to the subject via various routes and provide good bioavailability of the active. The compositions are generally clear and non-turbid and are useful, for example, for preparing formulations of cannabinoid compounds.

The present disclosure relates to compositions comprising an oil-in-water nano-emulsion dispersed in an external oil phase, methods for the preparation of such compositions as well as uses of such compositions, for example, for delivery of active ingredients to a subject. The methods comprise combining a first mixture comprising a liquid oil and a charged lipid with a second mixture that is an aqueous mixture comprising a film-forming thermoreversible emulsifier to prepare an oil-in-water nano-emulsion; and combining the oil-in-water nano-emulsion with a third mixture comprising a combination of solid lipids to prepare the composition.

The present disclosure relates to compositions comprising an oil-in-water nano-emulsion dispersed in an external oil phase, methods for the preparation of such compositions as well as uses of such compositions, for example, for delivery of active ingredients to a subject. The methods comprise combining a first mixture comprising a liquid oil and a charged lipid with a second mixture that is an aqueous mixture comprising a film-forming thermoreversible emulsifier to prepare an oil-in-water nano-emulsion; and combining the oil-in-water nano-emulsion with a third mixture comprising a combination of solid lipids to prepare the composition.

The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition. The method comprising topically administering a pharmaceutical composition comprising Capecitabine or a hydrate or solvate thereof to the affected area of the skin of the subject, to form therapeutically effective amounts of FU within the skin.

Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

An embodiment of a CBD or other cannabinoid or terpene or lipid-soluble Nano-Emulsion material and the process comprises a formulation comprising at least a lecithin or mixed lecithin, one or more carrier oils, and a Vitamin E TPGS from a sunflower version and a soy version or Polysorbate 80, 60 or 65. Among either version, the versions may further comprise mixed tocopherols and still further comprise at least one of; an LCT oil, an olive oil, and coconut oil. Any one of the versions may further comprise at least one of; sodium benzoate, potassium sorbate, and sorbic acid, and even yet further comprise purified water. Some embodiments may comprise a Vitamin E acetate or beeswax.